CGT Global

Cryopreserved leukopaks and isolated cells available when you need them. CGT Global supplies ready to ship cryopreserved leukopaks, PBMCs, T cells, B cells, NK cells, monocytes, and other primary human cell types. All material includes full donor metadata and QC. No donor scheduling. No delays. This is the right time to • Replenish for upcoming winter studies • Lock in materials for early 2026 planning • Use remaining annual budget while supply is still available If you want access to the full inventory list and this month’s savings, reach out to [email protected] or start a live chat here https://lnkd.in/gpnXzj2w and our team will provide details. Inventory moves quickly every December, so now is the window to secure what you need and maintain continuity into the new year. From our team to yours, we hope you have a productive December and a smooth finish to the year. Thank you for your continued partnership.

Cryo just got cooler 50% OFF all cryo inventory! For a limited time, CGT Global is offering half off our entire cryogenic inventory including: Cryopreserved Leukopaks - 2.5 Billion to 10 Billion TNCs from diverse donors Diseased State Samples - including Behcet’s disease, Lyme’s disease, and SLE (Systemic Lupus Erythematosus) samples Whether you’re working in cell therapy, immunology, or translational research, this is your chance to secure high-quality, ethically sourced materials, at unprecedented savings. 🚨 Offer valid while inventory lasts. 👉 https://lnkd.in/gN6g6GZs #Cryo #LifeSciences #Biotech #Research #CellTherapy #CGTGlobal #Innovation

The numbers say it all: the preclinical and translational research market is exploding. The global mice model market alone is projected to grow from $1.73B in 2025 to $4.1B by 2034, expanding at a 10.04% CAGR. 🚀 Why? Because pharma, biotech, and academic researchers need reliable models to accelerate R&D in oncology, neuroscience, immunology, and beyond. And at the foundation of many of these studies? High-quality stem and engraftment cells. At CGT Global, we’re meeting this demand with: 🔹 CD34+ hematopoietic stem/progenitor cells – consistently >95% purity and >90% viability post-thaw 🔹 Engraftment-ready cells – validated for reliable preclinical performance 🔹 Superior engraftment rates in validated in vivo models – ensuring faster, more reliable study outcomes 🔹 Flexible sourcing – tailored to support everything from discovery research to IND-enabling studies As R&D spend rises and timelines shrink, reproducibility and quality can’t be left to chance. If your programs depend on engraftment, use us for the cells that move your science forward. 👉 Connect today to see how we can support your pipeline. #CellTherapy #CD34 #Engraftment #PreclinicalResearch #Biotech #CGTGlobal

Inconsistent mouse model engraftments don’t just cause frustration — they derail research timelines, inflate budgets, and put entire projects at risk. For many labs, the challenges are all too familiar: Unreliable outcomes that force repeat studies and waste valuable resources. Low success rates that create bottlenecks in preclinical pipelines. Slow timelines that delay publications, drug discovery, and translational progress. Data reproducibility issues that undermine credibility with partners, reviewers, and regulators. When you’re working with CD34+ humanized mouse models, you need consistency. You need confidence that each engraftment will deliver predictable, reliable results. And you need a partner that understands how high the stakes are for your research. That’s where we come in. Our CD34+ engraftment services are designed to eliminate the pain points that slow your science down. With proven methodologies and optimized processes, we deliver: ✅ High engraftment success rates — reducing the risk of failed studies. ✅ Streamlined timelines — so you can move from planning to discovery faster. ✅ Reproducible outcomes — ensuring your data stands up to scrutiny and drives real progress. ✅ Expert support — from a team that knows the difference between acceptable results and exceptional ones. Whether your focus is drug development, immunology, oncology, or translational research, our models provide the reliability you need to generate insights that matter. Instead of troubleshooting failed engraftments or repeating experiments, your team can stay focused on breakthroughs. Because at the end of the day, reliable data starts with reliable models. Don’t let engraftment challenges hold your research back. Choose a partner that delivers consistency, speed, and results you can trust.

Humanized mouse work is surging, and it runs on CD34+ engraftment. Per BioSpace: the humanized mouse model market is $141.72M (2024) → $150M (2025) → $250.94M by 2034 (5.84% CAGR). 📌 North America leads; APAC is the fastest-growing. 📌 Cell-based models (CD34, PBMC, BLT) are the fastest riser. Translation: if you’re running immuno-oncology, infectious disease, or hematopoiesis studies, your outcomes live or die on reliable human cell engraftment. At CGT Global, we’re meeting this demand with: 🔹 CD34+ hematopoietic stem/progenitor cells – consistently >95% purity and >90% viability post-thaw 🔹 Engraftment-ready cells – validated for reliable preclinical performance 🔹 Superior engraftment rates in validated in vivo models – ensuring faster, more reliable study outcomes 🔹 Flexible sourcing – tailored to support everything from discovery research to IND-enabling studies 👉 Connect today to see how we can support your pipeline. If your program depends on humanized mice, use us for the cells that make the model work. #HumanizedMice #CD34 #Engraftment #ImmunoOncology #Preclinical #CGTGlobal

Skip the bots. At CGT Global, you get a real scientist to support your CD34+ needs — with fast turnaround and expert guidance.